- Home
- EVT vs IMCR Comparison
EVT vs IMCR Comparison
Compare EVT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- IMCR
- Stock Information
- Founded
- EVT 2003
- IMCR 2008
- Country
- EVT United States
- IMCR United Kingdom
- Employees
- EVT N/A
- IMCR N/A
- Industry
- EVT Finance Companies
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVT Finance
- IMCR Health Care
- Exchange
- EVT Nasdaq
- IMCR Nasdaq
- Market Cap
- EVT 1.9B
- IMCR 1.7B
- IPO Year
- EVT N/A
- IMCR 2021
- Fundamental
- Price
- EVT $24.54
- IMCR $34.26
- Analyst Decision
- EVT
- IMCR Buy
- Analyst Count
- EVT 0
- IMCR 9
- Target Price
- EVT N/A
- IMCR $57.00
- AVG Volume (30 Days)
- EVT 115.5K
- IMCR 287.1K
- Earning Date
- EVT 01-01-0001
- IMCR 11-05-2025
- Dividend Yield
- EVT 8.32%
- IMCR N/A
- EPS Growth
- EVT N/A
- IMCR N/A
- EPS
- EVT 6.63
- IMCR N/A
- Revenue
- EVT $69,404,302.00
- IMCR $356,145,000.00
- Revenue This Year
- EVT N/A
- IMCR $29.71
- Revenue Next Year
- EVT N/A
- IMCR $11.27
- P/E Ratio
- EVT $3.55
- IMCR N/A
- Revenue Growth
- EVT N/A
- IMCR 26.78
- 52 Week Low
- EVT $19.20
- IMCR $23.15
- 52 Week High
- EVT $25.83
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- EVT 60.30
- IMCR 49.34
- Support Level
- EVT $24.41
- IMCR $33.92
- Resistance Level
- EVT $24.52
- IMCR $37.00
- Average True Range (ATR)
- EVT 0.26
- IMCR 1.45
- MACD
- EVT 0.03
- IMCR -0.06
- Stochastic Oscillator
- EVT 72.65
- IMCR 39.78
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.